Compare COGT & CACC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COGT | CACC |
|---|---|---|
| Founded | 2014 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.0B |
| IPO Year | 2018 | 1996 |
| Metric | COGT | CACC |
|---|---|---|
| Price | $34.21 | $578.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 2 |
| Target Price | $36.21 | ★ $505.00 |
| AVG Volume (30 Days) | ★ 2.2M | 136.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.00 |
| EPS | N/A | ★ 12.40 |
| Revenue | $7,871,000.00 | ★ $2,317,200,000.00 |
| Revenue This Year | N/A | $91.73 |
| Revenue Next Year | $1,733.58 | $3.58 |
| P/E Ratio | ★ N/A | $47.03 |
| Revenue Growth | N/A | ★ 7.16 |
| 52 Week Low | $8.80 | $401.90 |
| 52 Week High | $43.73 | $588.71 |
| Indicator | COGT | CACC |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 61.27 |
| Support Level | $33.26 | $529.10 |
| Resistance Level | $37.69 | N/A |
| Average True Range (ATR) | 1.43 | 20.00 |
| MACD | 0.29 | 0.28 |
| Stochastic Oscillator | 78.82 | 85.88 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.